Pfizer Inventory 2012-2026 | PFE
Pfizer inventory from 2012 to 2026. Inventory can be defined as the total value of inventories in all stages of completion.
- Pfizer inventory for the quarter ending March 31, 2026 was $11.468B, a 2.16% decline year-over-year.
- Pfizer inventory for 2024 was $10.851B, a 6.5% increase from 2023.
- Pfizer inventory for 2023 was $10.189B, a 13.45% increase from 2022.
- Pfizer inventory for 2022 was $8.981B, a 0.86% decline from 2021.
|
Pfizer Annual Inventory (Millions of US $) |
|
|---|---|
| 2024 | $10,851 |
| 2023 | $10,189 |
| 2022 | $8,981 |
| 2021 | $9,059 |
| 2020 | $8,020 |
| 2019 | $7,068 |
| 2018 | $7,508 |
| 2017 | $7,578 |
| 2016 | $6,783 |
| 2015 | $7,513 |
| 2014 | $5,663 |
| 2013 | $6,166 |
| 2012 | $6,076 |
| 2011 | $6,610 |
|
Pfizer Quarterly Inventory (Millions of US $) |
|
|---|---|
| 2025-09-30 | $11,468 |
| 2025-06-30 | $11,669 |
| 2025-03-31 | $10,852 |
| 2024-12-31 | $10,851 |
| 2024-09-30 | $11,721 |
| 2024-06-30 | $11,447 |
| 2024-03-31 | $10,892 |
| 2023-12-31 | $10,189 |
| 2023-09-30 | $10,204 |
| 2023-06-30 | $10,310 |
| 2023-03-31 | $9,541 |
| 2022-12-31 | $8,981 |
| 2022-09-30 | $9,513 |
| 2022-06-30 | $10,454 |
| 2022-03-31 | $9,979 |
| 2021-12-31 | $9,059 |
| 2021-09-30 | $8,640 |
| 2021-06-30 | $8,948 |
| 2021-03-31 | $8,493 |
| 2020-12-31 | $8,020 |
| 2020-09-30 | $9,295 |
| 2020-06-30 | $8,564 |
| 2020-03-31 | $8,423 |
| 2019-12-31 | $7,068 |
| 2019-09-30 | $8,222 |
| 2019-06-30 | $8,233 |
| 2019-03-31 | $8,029 |
| 2018-12-31 | $7,508 |
| 2018-09-30 | $8,184 |
| 2018-06-30 | $8,074 |
| 2018-03-31 | $8,148 |
| 2017-12-31 | $7,578 |
| 2017-09-30 | $7,925 |
| 2017-06-30 | $7,584 |
| 2017-03-31 | $7,415 |
| 2016-12-31 | $6,783 |
| 2016-09-30 | $7,507 |
| 2016-06-30 | $7,614 |
| 2016-03-31 | $7,578 |
| 2015-12-31 | $7,513 |
| 2015-09-30 | $7,678 |
| 2015-06-30 | $5,796 |
| 2015-03-31 | $5,786 |
| 2014-12-31 | $5,663 |
| 2014-09-30 | $6,355 |
| 2014-06-30 | $6,249 |
| 2014-03-31 | $6,066 |
| 2013-12-31 | $6,166 |
| 2013-09-30 | $6,482 |
| 2013-06-30 | $6,282 |
| 2013-03-31 | $7,035 |
| 2012-12-31 | $6,076 |
| 2012-09-30 | $7,516 |
| 2012-06-30 | $7,001 |
| 2012-03-31 | $7,189 |
| 2011-12-31 | $6,610 |
| 2011-09-30 | $8,426 |
| 2011-06-30 | $8,597 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $153.074B | $62.579B |
| Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |